Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns

Pfizer Terminates Partnership:
Pfizer has ended its partnership with Sangamo Therapeutics to co-develop a gene therapy for hemophilia A, citing concerns over commercial viability and slow uptake of similar therapies25.

Sangamo Regains Rights:
Sangamo will regain full rights to the hemophilia A gene therapy program, including the investigational therapy giroctocogene fitelparvovec, which showed positive results in the Phase 3 AFFINE trial25.

Commercial Challenges:
The decision reflects broader challenges in the commercialization of gene therapies for rare diseases, including high costs and complex regulatory pathways45.

Pfizer's Gene Therapy Portfolio:
Pfizer has successfully approved a gene therapy for hemophilia B, Beqvez, but faces similar commercial challenges, including slow adoption and high pricing4.

Sangamo's Future Plans:
Sangamo plans to explore options to advance the hemophilia A gene therapy program, including seeking a new collaboration partner25.

Sources:

2. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-regain-full-rights-hemophilia-gene-therapy

4. https://www.biopharmadive.com/news/pfizer-fda-approval-beqvez-hemophilia-b-gene-therapy/714423/

5. https://www.pharmaceutical-technology.com/news/sangamos-stock-sinks-50-as-pfizer-halts-haemophilia-a-gene-therapy-partnership/